Skin Infiltration of Pathogenic Migratory and Resident T Cells Is Decreased by Secukinumab Treatment in Psoriasis

J Invest Dermatol. 2020 Oct;140(10):2073-2076.e6. doi: 10.1016/j.jid.2020.02.024. Epub 2020 Mar 19.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal, Humanized / pharmacology
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Cell Movement / drug effects
  • Humans
  • Interleukin-17 / analysis
  • Interleukin-17 / antagonists & inhibitors*
  • Psoriasis / drug therapy*
  • Psoriasis / immunology
  • Psoriasis / pathology
  • Severity of Illness Index
  • Skin / immunology
  • Skin / pathology*
  • T-Lymphocytes / drug effects*
  • T-Lymphocytes / physiology

Substances

  • Antibodies, Monoclonal, Humanized
  • IL17A protein, human
  • Interleukin-17
  • secukinumab

Associated data

  • UMIN-CTR/UMIN000023424